Tyr94
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.9
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr94  -  GAPDH (human)

Site Information
WGDAGAEyVVEstGV   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 25293196

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 ) , mutation of modification site ( 1 ) , western blotting ( 1 )
Disease tissue studied:
colorectal cancer ( 1 ) , colorectal carcinoma ( 1 ) , lung cancer ( 1 , 2 , 3 ) , non-small cell lung cancer ( 1 , 3 ) , non-small cell lung adenocarcinoma ( 1 , 2 )
Relevant cell line - cell type - tissue:

Downstream Regulation
Effects of modification on GAPDH:
enzymatic activity, induced ( 1 )

References 

1

Phadke M, et al. (2015) Disruption of NAD(+) binding site in glyceraldehyde 3-phosphate dehydrogenase affects its intranuclear interactions. World J Biol Chem 6, 366-78
26629320   Curated Info

2

Tsai CF, et al. (2015) Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. Nat Commun 6, 6622
25814448   Curated Info

3

Moritz A (2007) CST Curation Set: 2778; Year: 2007; Biosample/Treatment: cell line, NCI-H3255/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info